Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Durect Corporation

DRRX
Current price
0.65 USD +0.0018 USD (+0.28%)
Last closed 0.62 USD
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 19 687 074 USD
Yield for 12 month +67.13 %
Week
Month
Year
DRRX
21.11.2021 - 28.11.2021

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. Address: 10260 Bubb Road, Cupertino, CA, United States, 95014-4166

Analytics

WallStreet Target Price

6.75 USD

P/E ratio

Dividend Yield

1.17 %

Current Year

+19 283 000 USD

Last Year

+13 977 000 USD

Current Quarter

+1 744 000 USD

Last Quarter

+2 081 000 USD

Current Year

+17 695 000 USD

Last Year

+12 022 000 USD

Current Quarter

+1 432 000 USD

Last Quarter

+1 722 000 USD

Key Figures DRRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -41 964 000 USD
Operating Margin TTM -547.99 %
PE Ratio
Return On Assets TTM -42.74 %
PEG Ratio -0.46
Return On Equity TTM -148.81 %
Wall Street Target Price 6.75 USD
Revenue TTM 9 194 000 USD
Book Value 0.51 USD
Revenue Per Share TTM 0.37 USD
Dividend Share
Quarterly Revenue Growth YOY -85.4 %
Dividend Yield 1.17 %
Gross Profit TTM 16 480 000 USD
Earnings Share -1.53 USD
Diluted Eps TTM -1.53 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics DRRX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History DRRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 1.17 %
Last Split Factor 1:10
Payout Ratio
Last Split Date 06.12.2022
Dividend Date

Stock Valuation DRRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.3466
Price Sales TTM 3.9568
Enterprise Value EBITDA -1.8645
Price Book MRQ 2.3797

Financials DRRX

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators DRRX

For 52 weeks

0.47 USD 9.5 USD
50 Day MA 2.1 USD
Shares Short Prior Month 2 959 768
200 Day MA 3.89 USD
Short Ratio 10.36
Shares Short 3 847 133
Short Percent 15.64 %